Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 1.7%

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) shares fell 1.7% during trading on Thursday . The company traded as low as $6.28 and last traded at $6.19, 293,879 shares were traded during trading. A decline of 99% from the average session volume of 22,157,752 shares. The stock had previously closed at $6.30.

A number of brokerages have commented on TEVA. Cowen set a $9.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. UBS Group cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their price target for the company from $22.00 to $12.00 in a research report on Tuesday, May 28th. Bank of America cut shares of Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and cut their price target for the company from $19.00 to $9.00 in a research report on Thursday, May 30th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, May 2nd. Six investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.21.

The firm’s fifty day moving average price is $8.19 and its two-hundred day moving average price is $12.69. The stock has a market cap of $6.28 billion, a price-to-earnings ratio of 2.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.64. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.29 earnings per share for the current year.

In other news, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sol J. Barer bought 111,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was acquired at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after acquiring an additional 767 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 3.6% in the 1st quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock worth $384,000 after acquiring an additional 856 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after acquiring an additional 945 shares during the last quarter. Wedbush Securities Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 3.7% in the 1st quarter. Wedbush Securities Inc. now owns 28,385 shares of the company’s stock worth $445,000 after acquiring an additional 1,015 shares during the last quarter. Finally, HighPoint Advisor Group LLC raised its holdings in shares of Teva Pharmaceutical Industries by 8.7% in the 1st quarter. HighPoint Advisor Group LLC now owns 12,920 shares of the company’s stock worth $188,000 after acquiring an additional 1,035 shares during the last quarter. Institutional investors own 65.28% of the company’s stock.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Return on Equity (ROE)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.